ERBB3 and neoplasm: Taken together with the HER3 binding specificity of HPK, its blocking in vitro by HER3 peptide, overlap with HER3 on cell and tissue specimens, and the comparatively higher HER3 expression on tumor tissue, these studies strongly suggest that tumor targeting by HPK is directed predominantly by ligand-receptor binding to HER3-dense cells.